Robert J. Dow
Corporate Officer/Principal chez Faculty of Pharmaceutical Medicine
Profil
Robert J.
Dow currently works at Faculty of Pharmaceutical Medicine, as Member.
Dr. Dow also formerly worked at biolitec Pharma Ltd., as Chief Executive Officer from 2002 to 2005, Cell Genesys, Inc., as Chief Medical Officer & SVP-Medical Affairs from 2005 to 2008, Pharmaceutical Product Development LLC, as Vice President-Global Product Development, and Hoffmann-La Roche, Inc., as Head-Global Drug Development from 1995 to 1997.
Dr. Dow received his doctorate degree from the University Of Dundee and undergraduate degree from the University of St. Andrews.
Postes actifs de Robert J. Dow
| Sociétés | Poste | Début |
|---|---|---|
| Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | 28/10/2011 |
Anciens postes connus de Robert J. Dow
| Sociétés | Poste | Fin |
|---|---|---|
Pharmaceutical Product Development LLC
 Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Directeur Technique/Scientifique/R&D | 01/08/2019 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Directeur Technique/Scientifique/R&D | 30/10/2008 |
biolitec Pharma Ltd.
 biolitec Pharma Ltd. Medical SpecialtiesHealth Technology biolitec Pharma Ltd. produces and markets a photo technology platform for the treatment of head and neck cancer. Its product Foscan, is a porphyrin photosensitising device used for the treatment of head and neck cancer in patients who cannot be treated with other therapies. The company is headquartered in Dublin, Ireland. | President | 01/01/2005 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01/01/1997 |
Formation de Robert J. Dow
| University of St. Andrews | Undergraduate Degree |
| University Of Dundee | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
biolitec Pharma Ltd.
biolitec Pharma Ltd. Medical SpecialtiesHealth Technology biolitec Pharma Ltd. produces and markets a photo technology platform for the treatment of head and neck cancer. Its product Foscan, is a porphyrin photosensitising device used for the treatment of head and neck cancer in patients who cannot be treated with other therapies. The company is headquartered in Dublin, Ireland. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Pharmaceutical Product Development LLC
Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
| Faculty of Pharmaceutical Medicine |
